Funded Project Details - FY2021
|Title:|| Induction of Senescence using Dexamethasone to re-sensitize NSCLC to anti-PD1 therapy|
||Ann Arbor, MI
|Congressional District Code:
||Clinical Science R&D
|| July 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Lung cancer accounts for 30% of all cancers among American war Veterans, and remains the leading cause of cancer related deaths. Half of all lung cancers are metastatic non-small cell lung cancer (NSCLC), with a 2-year survival rate of 10%. Immunotherapy with immune checkpoint inhibitors (ICI) has emerged as a promising therapeutic strategy that aims to harness the immune system to fight lung cancer. However, given the modest response rates of 20-25%% to these ICIs and the desire to extend their...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.